With gene therapy for RPE65-associated retinal dystrophy being clinically available [6] and gene therapy for many other IRDs being developed [7], it is paramount to develop objective non-invasive measures of visual acuity and retinal function that can be used both to aid in patient selection for treatment and clinical trials as well as in the estimation of treatment effectivity. The gene discussed is RPE65; the disease is inherited retinal dystrophy.